-
April 2026
This virtual roundtable will bring together leaders from across Europe and beyond to consider the question of how Alzheimer’s treatments are adopted. While regulators in Europe have approved the first generation of disease-modifying therapies, payers have yet to follow — in contrast to countries such as the US and Japan. The discussion will explore how advocates mobilise urgency around access to diagnostics and treatments and what strategies might help shift the policy debate and how collaboration across the field could help secure future adoption.
-
April 2026
Chaired by Dr Fiona Carragher, Chief Policy and Research Officer at the Alzheimer’s Association, the meeting will feature opening presentations from Professor Vanessa Raymont of the University of Oxford and Professor Jeff Burns of the University of Kansas, followed by a round-table discussion. The dialogue will explore how new biomarker can move from research settings into real-world health systems.
-
April 2026
This breakfast roundtable will explore how advocacy must evolve as dementia enters an era of biomarkers, earlier diagnosis and the first disease-modifying treatments. As health systems begin to adopt new diagnostics and therapies, the focus of advocacy is also shifting earlier in the disease pathway. Dementia movements, often built around carers and support, now face the challenge of engaging people in pre-symptomatic or very early stages of disease. The discussion will examine what effective advocacy looks like for this emerging population.
-
October 2026
The 2026 WDC Summit will bring together international and UK leaders to examine how dementia practice is changing as diagnosis moves earlier and new treatments and prevention strategies emerge. The programme will explore the implications of this shift for clinical pathways, system organisation, and the experience of individuals who may live for longer periods in early-stage disease.
-
November 2026
The World Dementia Council 2026 WDC China Summit will take place on 14–15 November 2026 in Guangzhou. This two-day meeting will convene leading clinicians, researchers, and health system decision-makers from across China alongside international experts. The programme addresses: earlier and more precise diagnosis supported by biomarkers and updated diagnostic criteria; reatment delivery; the growing role of prevention; and the use of data to support long-term care.